Savara (SVRA) FCF Margin (2013 - 2020)

Savara (SVRA) posted quarterly FCF Margin of 1230500.0% for Q4 2020, down 46755.27% quarter-over-quarter from 2626.17% in Q3 2020.

Savara (SVRA) FCF Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has reported FCF Margin for 5 consecutive years, with 1230500.0% the latest figure, recorded in Q4 2020.

In Q4 2020, FCF Margin changed N/A year-over-year to 1230500.0%; the TTM figure through Mar 2022 stood at 3896000.0% (changed N/A YoY), while the FY2020 annual figure was 15518.68%, changed N/A from the prior year.
FCF Margin declined to 1230500.0% in Q4 2020 per SVRA's latest filing, from 2626.17% in the prior quarter.
Across five years, FCF Margin topped out at 8161.7% in Q2 2017 and bottomed at 1230500.0% in Q4 2020.
Historically, FCF Margin has averaged 205828.93% across 3 years, with a median of 2857.23% in 2020.
On a YoY basis, FCF Margin climbed as much as 3631231 bps in 2016 and fell as far as 3631231 bps in 2016.
Savara's FCF Margin stood at 547.5% in 2016, then jumped by 1591 bps to 8161.7% in 2017, then tumbled by 15177 bps to 1230500.0% in 2020.
Business Quant data shows SVRA's FCF Margin at 1230500.0% in Q4 2020, 2626.17% in Q3 2020, and 8161.7% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Savara	1.11 Bn	1.11 Bn	-	-

Download Data